BofA analyst Tazeen Ahmad lowered the firm’s price target on BioNTech (BNTX) to $130 from $134 and keeps a Buy rating on the shares. The firm adjusted targets among its small-to-mid cap biotech coverage as part of a Q3 earnings preview for the group.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BNTX:
- BioNTech commences public exchange offer for CureVac shares
- BioNTech price target lowered to $131 from $133 at Morgan Stanley
- BioNTech SE: Strategic AI Integration and Innovations Drive Buy Rating
- BioNTech Hosts Second AI Day to Showcase AI Integration
- BioNTech price target raised to $121 from $116 at JPMorgan